XML 135 R117.htm IDEA: XBRL DOCUMENT
v3.20.4

OTHER EXPENSE (INCOME), NET - Narrative (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018
Schedule Of Other Income And Expenses [Line Items] |  |  |
Favorable (unfavorable) adjustment, litigation and other matters | $ (422) | $ (1,401) | $ 27
Upfront payments, included in acquired in-process research and development costs | 32 | 41 | 1
Milestone achievement, included in net gain (loss) on other sales of assets | $ 1 | 31 | (6)
Milestone Payment Related To Certain Product |  |  |
Schedule Of Other Income And Expenses [Line Items] |  |  |
Milestone achievement, included in net gain (loss) on other sales of assets |  | $ 20 |
Salix Ltd. SEC Investigation Litigation |  |  |
Schedule Of Other Income And Expenses [Line Items] |  |  |
Favorable (unfavorable) adjustment, litigation and other matters |  |  | $ 40

X
- Definition [Line Items] for Schedule Of Other Income And Expenses [Table] + References No definition available. + Details
Name: | bhc_ScheduleOfOtherIncomeAndExpensesLineItems
Namespace Prefix: | bhc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details
Name: | us-gaap_GainLossOnDispositionOfAssets1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349 + Details
Name: | us-gaap_GainLossRelatedToLitigationSettlement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=bhc_SalixLtd.SECInvestigationLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |